CYTK — Cytokinetics, Incorporated Stock Price, Chart & AI Report

Neutral May 27, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Cytokinetics to Participate in June Investor Conferences

Cytokinetics announced that its management team will participate in two major investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. The company will host fireside chats at both events, with live webcasts available on its investor relations website.

CYTK investor conference Jefferies Global Healthcare Conference Goldman Sachs Healthcare Conference cardiac myosin inhibitor MYQORZO aficamten hypertrophic cardiomyopathy

Sentiment note

The announcement is routine corporate communication regarding investor conference participation. While the company has an approved drug (MYQORZO) and positive Phase 3 trial results (ACACIA-HCM), the article itself is purely informational about conference attendance without new clinical or financial developments that would warrant positive or negative sentiment.

Neutral May 18, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics granted stock options to purchase 20,807 shares and 13,793 RSUs to 8 newly hired employees on May 15, 2026 as material inducements to employment. The stock options have an exercise price of $75.85 per share and vest over 4 years, while RSUs vest over 3 years. The company is a specialty cardiovascular biopharmaceutical firm with its approved drug MYQORZO® for obstructive hypertrophic cardiomyopathy and several investigational candidates in development.

CYTK stock options RSUs employee compensation equity incentive plan cardiac myosin inhibitor MYQORZO® hypertrophic cardiomyopathy

Sentiment note

The article reports a routine employee equity grant as a hiring incentive, which is standard corporate practice. While the company has an approved drug (MYQORZO®) and positive clinical trial results (ACACIA-HCM), the main article focuses on administrative compensation matters rather than business developments or financial performance that would warrant positive or negative sentiment.

Positive May 12, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Cytokinetics announced that its management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The company will discuss its cardiovascular biopharmaceutical pipeline, including MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy and ongoing development of omecamtiv mecarbil and ulacamten for heart failure treatments.

CYTK cardiac myosin inhibitor hypertrophic cardiomyopathy heart failure clinical trial biopharmaceutical FDA approval MYQORZO®

Sentiment note

The company is advancing its pipeline with an approved drug (MYQORZO®) in multiple markets, positive Phase 3 trial results for aficamten in non-obstructive HCM, and multiple investigational candidates in development. The company is also raising capital ($805 million from recent public offering) to fund operations, indicating investor confidence and financial strength.

Neutral Apr 21, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Cytokinetics to Announce First Quarter Results on May 5, 2026

Cytokinetics announced it will report first quarter 2026 results on May 5, 2026, followed by a conference call at 4:30 PM ET. The specialty cardiovascular biopharmaceutical company will discuss financial results and provide business updates on its pipeline including MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy and investigational drugs omecamtiv mecarbil and ulacamten for various heart failure indications.

CYTK earnings report Q1 2026 cardiac myosin inhibitor MYQORZO aficamten hypertrophic cardiomyopathy heart failure

Sentiment note

The article is a routine earnings announcement with no material business developments, clinical trial results, or regulatory updates. It simply schedules a quarterly earnings call and provides standard company background information. No positive or negative catalysts are mentioned.

Neutral Mar 23, 2026 • 17:17 UTC The Motley Fool • Jonathan Ponciano

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital Management established a new $5.79 million position in clinical-stage biotech Biohaven, acquiring 513,184 shares during Q4 2025. Despite the stock falling 70% over the past year due to FDA rejection of troriluzole and disappointing trial results, the fund's investment signals potential turnaround prospects. Biohaven has refocused on late-stage programs including a degrader platform and Phase 2 obesity candidate with data expected in H2 2026, while maintaining a strengthened balance sheet with $500.9 million in cash.

BHVN CYTK NBIX biotech clinical-stage FDA rejection stock decline institutional investment

Sentiment note

Mentioned as a top holding in Sarissa's portfolio (11.3% of AUM) but no specific news or developments discussed in the article.

Neutral Mar 18, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics granted stock options to purchase 8,628 shares and 5,719 restricted stock units to 5 new employees hired in February and March 2026 as material inducements to employment. The stock options have an exercise price of $60.06 per share and vest over 4 years, while RSUs vest over 3 years with a 40-40-20 schedule.

CYTK stock options RSUs employee compensation equity incentive plan vesting schedule material inducement

Sentiment note

The article reports a routine employee equity grant announcement. While it indicates the company is hiring and investing in talent acquisition, this is standard corporate practice and does not provide material information about business performance, product development, or financial health. The grant itself is neither positive nor negative for shareholders.

Neutral Mar 9, 2026 • 18:18 UTC The Motley Fool • Sara Appino

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

Cytokinetics executive Andrew Callos exercised and sold 15,000 stock options for approximately $928,950 in early February 2026, weeks after the FDA approval and market launch of the company's first commercial cardiac drug, myqorzo. The transaction reduced his direct holdings by 22.9% to 50,440 shares. The sale comes as Cytokinetics transitions to commercial-stage operations following significant investment in launch readiness.

CYTK insider trading stock options cardiac drug FDA approval biotech commercial launch myqorzo

Sentiment note

The insider sale is a routine equity compensation event typical for biotech companies and does not indicate negative sentiment about company prospects. The timing coincides with the successful commercial launch of myqorzo and stock appreciation (92% gain in six months prior). However, the company posted a $785 million net loss in 2025 and faces execution risks in commercialization and cash burn management, warranting a neutral stance rather than positive.

Positive Feb 24, 2026 • 21:00 UTC GlobeNewswire Inc. • Cytokinetics, Incorporated

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

Cytokinetics announced FDA approval of MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy in December 2025, with U.S. commercial launch underway and first prescriptions dispensed. The company also received approvals from China's NMPA and European Commission. Cytokinetics reported $1.22 billion in cash and investments as of December 31, 2025, with 2026 guidance of $830-870 million in combined R&D and SG&A expenses. The company expects to report topline results from ACACIA-HCM in Q2 2026 and launch in Germany in Q2 2026.

CYTK SNY BAYRY MYQORZO aficamten hypertrophic cardiomyopathy FDA approval commercial launch

Sentiment note

Company achieved major regulatory milestone with FDA, European Commission, and China NMPA approvals for MYQORZO. U.S. commercial launch is underway with early prescribing activity reported. Strong balance sheet with $1.22 billion in cash provides runway for clinical development and commercialization. Multiple pipeline programs advancing (ACACIA-HCM, COMET-HF, AMBER-HFpEF) with expected topline results in 2026. However, significant net losses ($785 million in 2025) and high operating expenses ($830-870 million guidance for 2026) present financial challenges.

Positive Feb 19, 2026 • 08:30 UTC GlobeNewswire Inc. • Custom Market Insights

Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global ALS therapeutics market is valued at USD 812 million in 2024 and is projected to reach USD 1,964 million by 2035, growing at an 11.5% CAGR. Growth is driven by innovations in genetic therapies, gene-silencing technologies, improved diagnostics, and increased disease awareness. Key players include Biogen, Ionis Pharmaceuticals, Amylyx Pharmaceuticals, and others developing disease-modifying treatments.

BIIB IONS AMLX CYTK ALS therapeutics gene therapy antisense oligonucleotide neurological disease

Sentiment note

Identified as a key market player developing therapies for ALS in a growing market with 11.5% CAGR

Positive Feb 12, 2026 • 21:00 UTC GlobeNewswire Inc. • Na

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Cytokinetics announced it will report fourth quarter 2025 results on February 24, 2026, followed by a conference call at 4:30 PM ET. The specialty cardiovascular biopharmaceutical company highlighted its approved cardiac myosin inhibitor MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy, with a European Commission decision expected in Q1 2026. The company is also developing omecamtiv mecarbil and ulacamten for various heart failure indications.

CYTK earnings report cardiac myosin inhibitor hypertrophic cardiomyopathy MYQORZO aficamten heart failure FDA approval

Sentiment note

The company has an FDA-approved drug (MYQORZO) with positive European regulatory momentum (CHMP positive opinion), a robust pipeline with multiple investigational candidates in development, and over 25 years of scientific innovation in muscle biology. The expected European Commission decision in Q1 2026 represents a near-term catalyst for potential market expansion.

Neutral Jan 20, 2026 • 21:00 UTC GlobeNewswire Inc. • Na

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics granted stock options to purchase 29,416 shares and 19,825 restricted stock units to 8 employees hired in December 2025 and January 2026 as material inducements to employment. The stock options have an exercise price of $63.44 per share and vest over 4 years, while RSUs vest over 3 years with a 40-40-20 schedule.

CYTK stock options RSUs employee compensation equity incentive plan cardiac myosin inhibitor MYQORZO hypertrophic cardiomyopathy

Sentiment note

The article announces routine employee equity grants as material inducements for new hires. While this indicates company growth and hiring activity, it is a standard HR practice with no material business impact disclosed. The sentiment is neutral as it neither represents positive business developments nor negative concerns.

Positive Jan 5, 2026 • 21:00 UTC GlobeNewswire Inc. • Na

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Cytokinetics' CEO Robert I. Blum is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company, a specialty cardiovascular biopharmaceutical firm, has FDA-approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy and is advancing a pipeline of cardiac muscle dysfunction treatments.

CYTK SNY cardiac myosin inhibitor hypertrophic cardiomyopathy MYQORZO aficamten FDA approval heart failure

Sentiment note

The company has achieved FDA approval for MYQORZO and received NMPA approval in China, triggering a $7.5 million milestone payment from Sanofi. The company is presenting at a major healthcare conference and has multiple drug candidates in development, indicating strong progress in its pipeline and market expansion.